Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
This is a single arm, single cencer, phase II clinical trial. This study aims to evaluate the efficacy and safety of Cadonilimab combined with S-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.
Pancreatic Neoplasms
DRUG: Cadonilimab+S-1or Capecitabine
Objective response rate (ORR), Defined as the proportion of patients with a complete response or partial response to treatment according to RECIST1.1, Up to 2 years
Overall survival (OS), Defined as the length of time from the first dose to death from any cause., Up to 2 years|Progression-free survival (PFS), Defined as the length of time from the first dose to progression disease or death from any cause., Up to 2 years|Disease control rate (DCR), Defined as the proportion of patients with a complete response, partial response or stable disease to treatment according to RECIST1.1, Up to 2 years|Duration of response (DoR), Defined as the length of time from first tumor response (CR or PR) to disease progression (PD) or death., Up to 2 years
Biomarker analysis, Biomarkers that potentially predict efficacy include, but are not limited to, PD-L1 expression and T cell subpopulations in tumor tissue specimens or blood samples and so on., Up to 2 years
This is a single arm, single cencer, phase II clinical trial. This study aims to evaluate the efficacy and safety of Cadonilimab combined with S-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.